LFST

LifeStance Health Group Inc

Add to Watchlist

Advanced Chart

5.640

+0.11(1.989%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.660

Open

5.550

VWAP

5.55

Vol

1.26M

Mkt Cap

2.19B

Low

5.460

Amount

7.02M

EV/EBITDA(TTM)

37.36

Total Shares

382.29M

2.25B

EV/OCF(TTM)

15.35

P/S(TTM)

1.62

LifeStance Health Group, Inc. is a reimagining mental health company. The Company is focused on providing virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Its patient-focused platform combines differentiated clinical capabilities with a personalized, digitally powered patient experience designed to transform patient access and treatment. Its clinicians offer patients a comprehensive, multidisciplinary suite of mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders and post-traumatic stress disorder. It employs approximately 7,400 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

381.38M

+14.54%

0.002

-107.75%

379.74M

+16.66%

-0.007

-64%

356.03M

+13.85%

-0.026

-56.55%

Estimates Revision

The market is revising Upward the revenue expectations for LifeStance Health Group, Inc. (LFST) for FY2025, with the revenue forecasts being adjusted by 0.13% over the past three months. During the same period, the stock price has changed by 19.24%.

Revenue Estimates for FY2025

Revise Upward

+0.13%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-54.23%

In Past 3 Month

Stock Price

Go Up

+19.24%

In Past 3 Month

6 Analyst Rating

43.62% Upside

Wall Street analysts forecast LFST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFST is 8.10 USD with a low forecast of 5.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

43.62% Upside

Current: 5.640

Low

5.50

Averages

8.10

High

10.00

43.62% Upside

Current: 5.640

Low

5.50

Averages

8.10

High

10.00

UBS

Buy

maintain

2025-08-08

Reason

UBS

Price Target

2025-08-08

maintain

Buy

Reason

UBS raised the firm's price target on LifeStance to $9 from $8.50 and keeps a Buy rating on the shares.

BTIG

Buy

initiated

2025-07-25

Reason

BTIG

Price Target

2025-07-25

initiated

Buy

Reason

BTIG initiated coverage of LifeStance with a Buy rating and $8 price target. The firm says LifeStance is one of the country's largest outpatient mental health providers. It notes that 90% of the company's patients are commercially insured, making it well networked into health systems and referring hospitals. BTIG believes commercially insured lives are the most attractive segment of the market since insurance rates are typically well above Medicare and Medicaid rates. LifeStance is differentiated given its in-person and virtual care model, the analyst tells investors in a research note.

UBS

Kevin Caliendo

Neutral -> Buy

upgrade

$8.50

2025-05-27

Reason

UBS

Kevin Caliendo

Price Target

$8.50

2025-05-27

upgrade

Neutral -> Buy

Reason

UBS analyst Kevin Caliendo upgraded LifeStance to Buy from Neutral with an unchanged price target of $8.50. The firm we sees a fundamental disconnect between the company's underlying performance and the stock's valuation today. The recent stock weakness is related to investor de-risking and "some perhaps misunderstood headlines" coming out of the Q1 print, the analyst tells investors in a research note. UBS says there is "noise" surrounding LifeStance's pause in federal enforcement of the mental health parity rule, which should have no impact to reimbursement rates or its rate improvement trajectory.

Keybanc

Steve Dechert

Buy

Initiates

2025-04-08

Reason

Keybanc

Steve Dechert

Price Target

2025-04-08

Initiates

Buy

Reason

KeyBanc initiated coverage of LifeStance with an Overweight rating and $9 price target. The firm expects mid-teens organic sales growth over the next couple of years from the company, driven mainly by higher visit volumes on further clinician adds and increasing total revenue per visit on payor reimbursement rate improvement. It also expects margin expansion on the company's recently optimized real estate footprint, clinician productivity, higher margin specialty offerings, and continued cost efficiencies driven by technology enhancements.

Canaccord Genuity

Richard Close

Strong Buy

Initiates

2025-04-03

Reason

Canaccord Genuity

Richard Close

Price Target

2025-04-03

Initiates

Strong Buy

Reason

Canaccord analyst Richard Close initiated coverage of LifeStance with a Buy rating and $8 price target. LifeStance is the largest clinic-based therapy provider, serving its clients both through in-person and virtual visits, the analyst tells investors in a research note. The firm says the company offers the only hybrid, in-person and virtual therapy company to invest in. It believes LifeStance's acquisition strategy offers growth upside.

Goldman Sachs

Jamie Perse

Hold

Strong Buy

Upgrades

$10

2024-12-16

Reason

Goldman Sachs

Jamie Perse

Price Target

$10

2024-12-16

Upgrades

Hold

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for LifeStance Health Group Inc (LFST.O) is 341.36, compared to its 5-year average forward P/E of -12.52. For a more detailed relative valuation and DCF analysis to assess LifeStance Health Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-12.52

Current PE

341.36

Overvalued PE

70.68

Undervalued PE

-95.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

46.27

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

79.78

Undervalued EV/EBITDA

12.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.01

Current PS

0.00

Overvalued PS

5.28

Undervalued PS

0.74